Results 1 to 10 of about 100,511 (312)

Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study [PDF]

open access: yesBMC Medicine
Background Several antiarrhythmic drugs can interact with direct oral anticoagulants (DOACs) through pharmacokinetic mechanisms increasing DOAC levels. Our multinational cohort study assessed the effectiveness and safety of concomitant use of DOACs and ...
Fabian Maximilian Meinert   +5 more
doaj   +2 more sources

Synthesis and In Vivo Antiarrhythmic Activity Evaluation of Novel Scutellarein Analogues as Voltage-Gated Nav1.5 and Cav1.2 Channels Blockers

open access: yesMolecules, 2023
Malignant cardiac arrhythmias with high morbidity and mortality have posed a significant threat to our human health. Scutellarein, a metabolite of Scutellarin which is isolated from Scutellaria altissima L., presents excellent therapeutic effects on ...
Wei Yang   +10 more
doaj   +1 more source

Physicochemical stability of 20 mg/mL amiodarone hydrochloride oral suspension in SyrSpend® SF PH4 (liquid)

open access: yesPharmaceutical Technology in Hospital Pharmacy, 2022
Amiodarone hydrochloride is a class III antiarrhythmic drug indicated for the treatment of ventricular and supraventricular tachycardias. Oral amiodarone is only available in a tablet dosage form, which is not suitable for pediatric use. The stability of
Adoum Anissa   +5 more
doaj   +1 more source

Investigation of 1,4-Substituted 1,2,3-Triazole Derivatives as Antiarrhythmics: Synthesis, Structure, and Properties

open access: yesPharmaceuticals, 2022
Here, we investigated the reaction of 1,3-dipolar cycloaddition of 1,3-diazido-2-nitro-2- azapropane (DANP) to propargyl alcohol over a copper-based catalyst and identified the optimum reaction conditions that enable the synthesis of 2-nitro-1,3-bis(4,4′-
Elena O. Shestakova   +8 more
doaj   +1 more source

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms

open access: yesFrontiers in Pharmacology, 2020
Since the clinical use of digitalis as the first pharmacological therapy for atrial fibrillation (AF) 235 years ago in 1785, antiarrhythmic drug therapy has advanced considerably and become a cornerstone of AF clinical management.
Meng Geng, Andrew Lin, Thao P. Nguyen
doaj   +1 more source

Antiarrhythmic Drug Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy

open access: yesBiomedicines, 2023
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable progressive myocardial disorder that predisposes patients to ventricular arrhythmias and sudden cardiac death.
Sean P. Gaine, Hugh Calkins
doaj   +1 more source

Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner

open access: yesFrontiers in Pharmacology, 2021
Atomoxetine, a neuroactive drug, is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). It is primarily known as a high affinity blocker of the noradrenaline transporter, whereby its application leads to an increased level of ...
Karl Josef Föhr   +5 more
doaj   +1 more source

Attenuation and Structural Transformation of Crassicauline A During Sand Frying Process and Antiarrhythmic Effects of its Transformed Products

open access: yesFrontiers in Pharmacology, 2021
To ensure safety and efficacy, most Aconitum herbs should be processed before clinical application. The processing methods include boiling, steaming, and sand frying.
Pei Tao, Yan Wang, Yujie Wang
doaj   +1 more source

Usefulness of body surface mapping to differentiate patients with Brugada syndrome from patients with asymptomatic Brugada syndrome. [PDF]

open access: yes, 2004
We attempted to determine the usefulness of body surface mapping (BSM) for differentiating patients with Brugada syndrome (BS) from patients with asymptomatic Brugada syndrome (ABS).
Emori, Tetsuro   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy